natgillin/translations-raw huggingface dataset:
Samtidig brug af Aptivus plus lavdosis ritonavir med flecainid, propafenon eller metoprolol er kontraindiceret (se pkt.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with flecainide, propafenone or metoprolol is contraindicated (see section 4.3)
LÆGEMIDLETS NAVN Aptivus 250 mg bløde kapsler tipranavir
NAME OF THE MEDICINAL PRODUCT Aptivus 250 mg soft capsules tipranavir
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE BEHOLDER/INDRE EMBALLAGE
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE/IMMEDIATE PACKAGING
Der bør udvises forsigtighed ved brug af carbamazepin sammen med Aptivus og lavdosis ritonavir.
Carbamazepine should be used with caution in combination with Aptivus, co-administered with low dose ritonavir.
Behandlingen med Aptivus MÅ IKKE standses medmindre lægen siger, at dit barns behandling skal afbrydes.
Your child must NOT stop taking Aptivus unless your child's doctor instructs to do so.
- nyrefunktionsfejl - influenza-lignende symptomer (generel sygdomsfølelse) - feber - vægttab - forhøjet indhold af bugspytkirtel-enzymet amylase i blodet - stigning i aktiviteten af leverenzymer - leverbetændelse med levercelleskade grundet udskillelse af et toksin (et giftstof)
Fever - Weight loss - Increased blood levels of the pancreas enzyme amylase - Increases in liver enzyme activity - Hepatitis with liver cell damage due to influence of a toxin
Kombinationsbehandling med proteasehæmmere anbefales generelt ikke, jf. de gældende behandlingsguidelines.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended
In vitro-studier viser, at tipranavir hæmmer trombocytaggregationen ved koncentrationer på niveau med de koncentrationer, der ses hos patienter i Aptivus med ritonavir behandling.
In in vitro experiments, tipranavir was observed to inhibit human platelet aggregation at levels consistent with exposures observed in patients receiving Aptivus with ritonavir.
Anden medicin, som Aptivus kan påvirke, omfatter: - p-piller eller kvindelige kønshormoner: hvis du tager p-piller, som prævention, skal du desuden anvende en anden præventionsform (f.eks. kondom).
Other medicines with which Aptivus may interact include: - oral contraceptives/hormone replacement therapy (HRT): If you are taking the contraceptive pill to prevent pregnancy you should use an additional or different type of contraception (e.g. barrier contraception like condoms).
Administration af didanosin som enterotabletter og Aptivus bløde kapsler plus lavdosis ritonavir, bør foregå med mindst 2 timers mellemrum for at undgå uforligelighed mellem formuleringerne.
administered with low dose ritonavir, should be separated by at least 2 hours to avoid formulation incompatibility.
- tolterodin (anvendes til behandling af overaktiv blære (herunder symptomer som hyppig vandladning, vandladningstrang eller ufrivillig vandladning)) - boceprevir og telaprevir (til behandling af hepatitis C) - cobicistat og medicin, der indeholder cobicistat (anvendes til at øge virkningen af hiv-medicin).
- bosentan (used to treat pulmonary artery hypertension) - halofantrine or lumefantrine (used to treat malaria) - tolterodine (used to treat overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)) - boceprevir and telaprevir (used to treat hepatitis C) - cobicistat and products containing cobicistat (used to increase effectiveness of HIV medicines).
Virkningsmekanismen menes at være tipranavir/ritonavirs induktion af glucuronosyltransferase.
The mechanism of action is thought to be induction of glucuronosyltransferase by tipranavir/r.
Atazanavir/ritonavir 300/100 mg x 1 (TPV/r 500/100 mg x 2)
Atazanavir/ritonavir 300/100 mg QD (TPV/r 500/100 mg BID)
Patienterne, med en påkrævet baseline hiv-1 RNA-koncentration på mindst 1500 kopier/ml, blev opdelt i aldersgrupperne (2 til< 6 år, 6 til < 12 år og 12 til 18 år), og blev randomiseret til en af de to dosisregimer med tipranavir med ritronavir: 375 mg/m2/150 mg/m2 dosis,
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two nonprotease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Midazolam Cmax ↔ Midazolam AUC ↑ 5,1 gange
Midazolam Cmax ↔ Midazolam AUC ↑ 5.1 fold
Teoretisk forventes det, at samtidig administration af tipranavir plus lavdosis ritonavir og alfuzosin øger plasmakoncentrationen af alfuzosin, hvilket kan forårsage hypotension.
Based on theoretical considerations, co-administration of tipranavir with low dose ritonavir and alfuzosin results in increased alfuzosin concentrations and may result in hypotension.
Sjælden (kan forekomme hos op til 1 ud af 1000 patienter): - leversvigt (med dødeligt udfald) - leverbetændelse - fedtlever - forhøjet indhold af bilirubin i blodet (et nedbrydningsprodukt af hæmoglobin) - væskemangel (dehydrering) - vægttab i ansigtet - blødning i hjernen *(se ovenfor) - forhøjet indhold af bugspytkirtel-enzymet lipase i blodet.
Rare: may affect up to 1 in 1,000 people - Liver failure (including fatal outcome) - Hepatitis - Fatty liver - Increased blood levels of bilirubin (a breakdown product of haemoglobin) - Dehydration (when the body does not have enough water) - Thinning of the face - Bleeding in the brain* (see above) - Increased blood levels of the pancreas enzyme lipase
De samme CYPP450 og P-gp interaktioner som for Aptivus 500 mg kapsler med 200 mg ritonavir sås i den arm af studiet, som blev udført med Aptivus oral opløsning/ritonavir 500mg/200mg.
This study was also conducted with Aptivus oral solution 500 mg with ritonavir 200 mg and showed the same CYP P450 and P-gp interactions as the Aptivus capsule 500 mg with ritonavir 200 mg. Based on the results from this study, Aptivus oral solution might be expected to have a similar interaction profile as the capsules.
Vend bunden i vejret på flasken, og træk forsigtigt Aptivus-dosis ned i den orale sprøjte.
Turn the bottle upside down and gently withdraw the required amount of Aptivus oral solution.
Fortæl det altid til lægen eller apotekspersonalet, hvis dit barn tager anden medicin eller har gjort det for nylig.
Tell your child's doctor or pharmacist if your child is taking, has recently taken or might take any other medicines, including medicines obtained without a prescription.
Aptivus skal tages sammen med følgende medicin:
You must take Aptivus together with:
500 mg tipranavir plus lavdosis ritonavir (200 mg); to gange daglig resulterede i en 29 gange øgning af den geometriske middelværdi for den minimale morgen-steady state plasmakoncentration sammenlignet med tipranavir 500 mg to gange daglig uden ritonavir.
500 mg Tipranavir co-administered with low dose ritonavir (200 mg; twice daily) was associated with a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations compared to tipranavir 500 mg twice daily without ritonavir.
Ved en overdosering må der generelt forventes, at der forekommer en øget frekvens og en højere sværhedsgrad af bivirkninger.
Generally, an increased frequency and higher severity of adverse reactions may result from overdose.
Teoretisk forventes det, at tipranavir plus lavdosis ritonavir øger koncentrationen af colchicin, pga. tipranavir/ritonavirs hæmning af CYP3A og P-gp.
Based on theoretical considerations, colchicine concentrations may increase upon co-administration with tipranavir and low dose ritonavir, due to tipranavir/ritonavir CYP3A and P-gp inhibition.
Behandlingsskift fra Aptivus kapsler til oral opløsning Aptivus kapsler kan ikke erstattes med den orale opløsning.
Switching from Aptivus capsules to the oral solution Aptivus capsules are not interchangeable with the oral solution.
Aluminium- og magnesiumbaserede antacida en gang daglig
Antacids aluminium- and magnesiumbased antacid QD
Mono-/diglycerider af capryl-/caprinsyre Propylenglycol
Mono/diglycerides of caprylic/capric acid Propylene glycol
Samtidig brug af Aptivus plus lavdosis ritonavir med dihydroergotamin, ergonovin, ergotamin eller methylergonovin er kontraindiceret på grund af risiko for alvorlige og/eller livstruende bivirkninger (se pkt.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with dihydroergotamine, ergonovine, ergotamine or methylergonovine is contraindicated due to potential serious and/or life threatening events (see section 4.3)
Aptivus plus lavdosis ritonavir bør derfor gives med mad.
Therefore Aptivus, co-administered with low dose ritonavir, should be given with food.
Dette betyder, at medicinen ikke virker efter hensigten, eller slet ikke virker.
If your HIV is resistant to some HIV medicines, this means that the medicine will not work so well, or will not work at all.
Det anbefales ikke at tage Aptivus sammen med etravirin.
Taking Aptivus with etravirine is not recommended.
Digoxin 0,25 mg x 1 p.o.
Digoxin 0.25 mg QD po
Hud og subkutane væv Almindelig udslæt
Skin and subcutaneous tissue disorders common rash uncommon pruritus, exanthem
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON/YDRE EMBALLAGE
PARTICULARS TO APPEAR ON THE OUTER FOLDING BOX/OUTER PACKAGING
Non-nukleosid reverse transkriptasehæmmere (NNRTI'er) Efavirenz 600 mg x 1
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg QD No clinically significant interaction is observed.
Din læge vil tage blodprøver, før du starter på Aptivus-behandlingen og under behandlingen.
Your doctor will monitor your liver function by blood tests before and during Aptivus treatment.
Anbefalinger ved samtidig behandling
Recommendations concerning co-administration
LÆGEMIDLETS NAVN Aptivus 100 mg/ml oral opløsning tipranavir
NAME OF THE MEDICINAL PRODUCT Aptivus 100 mg/ml oral solution tipranavir
Se også afsnit 2, ”p-piller eller kvindelige kønshormoner”.
See also Section 2, under “Oral contraceptives/hormone replacement therapy (HRT)”.
Antibiotika Clarithromycin 500 mg x 2 Clarithromycin Cmax ↔ Clarithromycin AUC ↑ 19% Clarithromycin Cmin ↑ 68%
Clarithromycin Cmax ↔ Clarithromycin AUC ↑ 19% Clarithromycin Cmin ↑ 68%
Loperamid Cmax ↓ 61% Loperamid AUC ↓ 51%
Loperamide 16 mg QD Loperamide Cmax ↓ 61% Loperamide AUC ↓ 51%
Triazolam Der er ikke udført interaktionsstudier.
Triazolam No interaction study performed
Opbevaring efter anbrud: 60 dage.
In use storage: 60 days, after first opening of the bottle.
Komparatorbehandlingen omfattede en ritonavir-boostet proteasehæmmer
There is a heterogeneous effect of telaprevir on ritonavir-boosted protease
LÆGEMIDLETS NAVN Aptivus 100 mg/ml oral opløsning
NAME OF THE MEDICINAL PRODUCT Aptivus 100 mg/ml oral solution
Lever og galdeveje Ikke almindelig forhøjede niveauer af leverenzymer (ALAT, ASAT), cytolytisk hepatitis, abnorm leverfunktionstest (ALAT, ASAT), toksisk hepatitis
Hepatobiliary disorders uncommon hepatic enzyme increased (ALAT, ASAT), cytolytic hepatitis, liver function test abnormal (ALAT, ASAT), hepatitis toxic rare hepatic failure (including fatal outcome), hepatitis, hepatic steatosis, hyperbilirubinaemia
Aptivus skal ikke ordineres til dit barn, hvis dit barn ikke tidligere har fået antiretroviral behandling, eller hvis anden antiretroviral behandling kan bruges.
Your child should not use Aptivusif they have never received antiretroviral therapy or have other antiretroviral options available.
Aptivus skal altid tages sammen med lavdosis ritonavir og andre antiretrovirale midler.
You must take Aptivus in combination with low dose ritonavir and other antiretroviral medicines.
Som følge af den metaboliske profil og iboende risiko for at fremkalde torsades de pointes kan indgivelse af halofantrin og lumefantrin med Aptivus plus lavdosisritonavir ikke anbefales (se pkt.
Due to their metabolic profile and inherent risk of inducing torsades de pointes, administration of halofantrine and lumefantrine with Aptivus, co-administered with low dose ritonavir, is not recommended (see section 4.4).
Rifabutin Cmax ↑ 70% Rifabutin AUC ↑ 190% Rifabutin Cmin ↑ 114%
Rifabutin 150 mg QD Rifabutin Cmax ↑ 70% Rifabutin AUC ↑ 190%
Der skal anvendes alternativ eller yderligere antikonception, når der gives østrogenbaseret oral antikonception sammen med Aptivus, plus lavdosis ritonavir (se pkt.
Alternative or additional contraceptive measures are to be used when oestrogen based oral contraceptives are co-administered with Aptivus co-administered with low dose ritonavir (see section 4.5).
Dosering Den anbefalede dosis for børn (i alderen 2 til 12 år) er 375 mg/m2 Aptivus sammen med 150 mg/m ritonavir to gange dagligt.
Posology The recommended dose for children (age 2 to 12 years) is 375 mg/m2 Aptivus co-administered with
Behandlingsskift fra Aptivus oral opløsning til kapsler Aptivus oral opløsning kan ikke erstattes med kapslerne.
Switching from Aptivus oral solution to the capsules Aptivus oral solution is not interchangeable with the capsules.
Samtidig behandling af pravastatin og Aptivus plus lavdosis ritonavir bør initieres med den lavest mulige pravastatindosis (10mg/dag), titreret til behandlingsrespons, og efterfulgt af nøje monitorering af symptomer forbundet med pravastatin, jævnfør indlægssedlen for pravastatin.
Co-administration of Aptivus, coadministered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.
Kombinationen af Aptivus plus lavdosis ritonavir, med enten omerprazol eller esomeprazol anbefales ikke (se pkt.
The combined use of Aptivus, coadministered with low dose ritonavir, with either omeprazole or esomeprazole is not recommended (see section 4.4).
Aptivus er kontraindiceret til patienter med moderat eller svær leverinsufficiens (Child-Pugh B eller C).
Aptivus is contraindicated in patients with moderate or severe (Child-Pugh Class B or C) hepatic insufficiency.
Ikke almindelig svimmelhed, perifer neuropati, døsighed
Nervous system disorders common headache uncommon dizziness, neuropathy peripheral, somnolence rare intracranial haemorrhage*
Samtidig brug af Aptivus plus lavdosis ritonavir med pimozid, sertindol, quetiapin eller lurasidon er kontraindiceret på grund af risiko for alvorlige og/eller livstruende bivirkninger, herunder koma (se pkt.
The concomitant use of Aptivus, co-administered with low dose ritonavir, with pimozide, sertindole, quetiapine or lurasidone is contraindicated due to potential serious and/or life threatening events, including coma (see section
- buprenorphin/naloxon (anvendes til behandling af stærke smerter) - ciclosporin, tacrolimus, sirolimus (anvendes til at forhindre organafstødning (at undertrykke immunforsvaret)) - warfarin (anvendes til behandling og forebyggelse af trombose) - digoxin (anvendes til behandling af hjertearytmier og hjertesvigt) - svampedræbende medicin, herunder fluconazol, itraconazol, ketoconazol eller voriconazol
- omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors used to reduce the gastric acid production) - metronidazole (used to treat infections) - disulfiram (used to treat alcohol dependence) - buprenorphine/naloxone (medicines used to treat severe pain) - cyclosporin, tacrolimus, sirolimus (used to prevent organ rejection (to suppress the immune system)) - warfarin (used to treat and prevent thrombosis) - digoxin (used to treat heart arrhythmias and heart failure) - antifungal medications including fluconazole, itraconazole, ketoconazole or voriconazole
Hvis du har: - forhøjede resultater af leverfunktionstest - hepatitis B eller C-infektion (leverbetændelse) er der en øget risiko for alvorlig eller evt. dødelig leverskade i den periode, hvor du tager Aptivus.
high liver function test results hepatitis B or C infection you are at increased risk of severe and potentially fatal liver damage while taking Aptivus.
For patienter med nedsat nyre- eller leverfunktion er samtidig administration af colchicin og Aptivus/ritonavir kontraindiceret (se pkt.
In patients with renal or hepatic impairment, coadministration of colchicine in patients on Aptivus/ritonavir is contraindicated (see section 4.3).
Voriconazol Der er ikke udført interaktionsstudier.
Voriconazole No interaction study performed
Samtidig behandling med tipranavir plus lavdosis ritonavir med proteasehæmmere anbefales derfor ikke.
Therefore, the co-administration of tipranavir, co-administered with low dose ritonavir, with protease inhibitors is not recommended.
40 mg x 2 > 60 kg 30 mg x 2 < 60 kg (TPV/r 750/100 mg x 2)
40 mg BID > 60 kg 30 mg BID < 60 kg (TPV/r 750/100 mg BID)
Metadon Cmax ↓ 55% Metadon AUC ↓ 53% Metadon Cmin ↓ 50%
Narcotic analgesics Methadone 5 mg QD Methadone Cmax ↓ 55% Methadone AUC ↓ 53% Methadone Cmin ↓ 50%
På grund af bosentans udtalte levertoksicitet og risiko for øget levertoksicitet ved samtidig administration af Aptivus plus lavdosis ritonavir frarådes kombinationen.
Due to the marked hepatotoxicity of bosentan and the potential for increasing the liver toxicity associated with Aptivus,co-administered with low dose ritonavir, this combination is not recommended.
Almindelig opkastning, flatulens, abdominalsmerter, abdominal distension, dyspepsi
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, flatulence, abdominal pain, abdominal distension, dyspepsia uncommon gastrooesophageal reflux disease, pancreatitis rare lipase increased
Som følge af den metaboliske profil og iboende risiko for at fremkalde torsades de pointes, kan indgivelse af halofantrin og lumefantrin sammen med Aptivus plus lavdosis ritonavir ikke anbefales.
Due to their metabolic profile and inherent risk of inducing torsades de pointes, administration of halofantrine and lumefantrine with Aptivus co-administered with low dose ritonavir, is not recommended.
Teoretisk forventes koncentrationerne af tipranavir eller ritonavir at øges ved samtidig behandling med itraconazol eller ketoconazol.
Based on theoretical considerations, tipranavir or ritonavir concentrations might increase upon co-administration with itraconazole or ketoconazole.
Tal med dit barns læge om det, hvis det fortsat ønsker at tage p-piller eller kvindelige kønshormoner.
You should check with your child's doctor if they do wish to continue taking oral contraceptives or HRT.
Samtidig administration af Aptivus plus lavdosis ritonavir med buprenorphin/naloxon kan resultere i en nedsat klinisk effekt af buprenorphin, da niveauerne for den aktive metabolit, norbuprenorphin, reduceres.
Due to reduction in the levels of the active metabolite norbuprenorphine, co-administration of Aptivus, coadministered with low dose ritonavir, and buprenorphine/naloxone may result in decreased clinical efficacy of buprenorphine.
Tipranavir plus lavdosis ritonavir forventes at øge desipraminkoncentrationerne.
Tipranavir, co-administered with low dose ritonavir, is expected to increase desipramine concentrations
Samtidig administration af etravirin og Aptivus/ritonavir anbefales ikke.
Co-administration of etravirine and Aptivus/ritonavir is not recommended.
Hvis kombinationen alligevel anses for nødvendig, anbefales det kraftigt både at monitorere sikkerheden af tipranavir og plasmakoncentrationerne for atazanavir (se pkt.
If the co-administration is nevertheless considered necessary, a close monitoring of the safety of tipranavir and a monitoring of plasma concentrations of atazanavir are strongly encouraged (see section
% med katagori C 29,2% Behandlingshistorik % med ARV
% with Category C 29.2% Treatment history % with any ARV 96.6% Median # previous
Første-dosis tipranavir/r: Digoxin Cmax ↔ Digoxin AUC ↔
First-dose tipranavir/r Digoxin Cmax ↔ Digoxin AUC ↔
C
In a
Almindelig (kan forekomme hos op til 1 ud af 10 patienter): - opkastning - mavesmerter - luft i maven - træthed - hovedpine - milde udslæt, f.eks. nældefeber eller fladt eller hævet udslæt med røde prikker - stigning i blodets lipid (fedt) niveauer - fordøjelsesbesvær (dyspepsi)
Common: may affect up to 1 in 10 people - Vomiting - Abdominal pain (tummy pain) - Flatulence (breaking wind more often) - Tiredness - Headache - Mild rashes e.g. with hives or with flat or raised small red spots - Increases in blood lipid (fat) levels - Dyspepsia
Er du i tvivl, så spørg dit barns læge eller apotekspersonalet.
- If you have any further questions, please ask your child's doctor or pharmacist.
Den kliniske relevans ved reduktionen af didanosinkoncentrationen er ikke fastlagt.
The clinical relevance of this reduction in didanosine concentrations has not been established.
Dosisjustering af tipranavir med ritonavir er ikke nødvendig.
No tipranavir with ritonavir dose adjustment is required.
Antimalaria Halofantrin Lumefantrin Der er ikke udført interaktionsstudier.
Antimalarial Halofantrine Lumefantrine No interaction study performed
Simvastatin Lovastatin Der er ikke udført interaktionsstudier.
Simvastatin Lovastatin No interaction study performed
Mavesmerter Feber
Hepatic impairment
Immunsuppressiva Ciclosporin Tacrolimus Sirolimus Der er ikke udført interaktionsstudier
Immunosupressants Cyclosporin Tacrolimus Sirolimus
Hver pakning indeholder 1 flaske med 95 ml oral opløsning samt en 5 ml oral sprøjte af klar polypropylen, en HDPE-sprøjtespids og en flaske-sprøjte adaptor af klar LDPE.
Amber glass bottle, with two-piece plastic child-resistant closure (outer shell high density polyethylene (HDPE), inner shell polypropylene resin with a foamed laminated polyethylene liner.. Each pack contains 1 bottle of 95 ml oral solution and is supplied with a clear polypropylene 5 ml oral syringe, HDPE syringe tip cap and clear LDPE bottle-syringe adapter.
Aptivus kaspler skal tages sammen med mad.
Aptivus capsules should be taken with food.
Der er ikke udført interaktionsstudier
No interaction study performed
Opbevares utilgængeligt for børn.
Aptivustreatment is therefore appropriate for your child.
Abacavir anbefales ikke samtidig med Aptivus plus lavdosis ritonavir med medmindre, der ikke er andre tilgængelige NRTI'er, som egner sig til patientbehandlingen.
The concomitant use of Aptivus, coadministered with low dose ritonavir, with abacavir is not recommended unless there are no other available NRTIs suitable for patient management.
Kapslen
Capsule contents
Den anbefalede daglige dosis for voksne eller unge fra 12 år er: - 500 mg (2 kapsler a 250 mg) Aptivus taget sammen med - 200 mg (2 kapsler a 100 mg) ritonavir 2 gange dagligt sammen med mad.
- 500 mg (two 250 mg capsules) Aptivus together with - 200 mg (two 100 mg capsules) ritonavir twice per day with food.
Da niveauerne af ethinylestradiol falder anbefales det, ikke at give kombinationen af Aptivus med ritonavir samtidig.
Since levels of ethinyl oestradiol are decreased, the co-administration of Aptivus co-administered with low dose ritonavir is not recommended.
Der er rapporteret systemiske kortikosteriod-effekter, herunder Cushings syndrom og adrenal suppression, hos patienter, der har fået ritonavir og inhaleret eller intranasalt administreret fluticasonproprionat.
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide.
Når Aptivus/ritonavir administreres sammen med telaprevir, kan der
When Aptivus/ritonavir is co-administered with telaprevir, a decrease or an increase of telaprevir exposure
Tipranavir metaboliseres i leveren.
Tipranavir is metabolised by the hepatic system.
Teoretisk forventes tipranavir plus lavdosis ritonavir at øge itraconazol- eller ketoconazolkoncentrationer.
Based on theoretical considerations tipranavir, co-administered with low dose ritonavir, is expected to increase itraconazole or ketoconazole concentrations.
Sådan skal du tage Aptivus
How to take Aptivus